Cargando…
Integration of Tumor Mutation Burden and PD-L1 Testing in Routine Laboratory Diagnostics in Non-Small Cell Lung Cancer
In recent years, Non-small cell lung cancer (NSCLC) has evolved into a prime example for precision oncology with multiple FDA-approved “precision” drugs. For the majority of NSCLC lacking targetable genetic alterations, immune checkpoint inhibition (ICI) has become standard of care in first-line tre...
Autores principales: | Schatz, Stefanie, Falk, Markus, Jóri, Balázs, Ramdani, Hayat O., Schmidt, Stefanie, Willing, Eva-Maria, Menon, Roopika, Groen, Harry J. M., Diehl, Linda, Kröger, Matthias, Wesseler, Claas, Griesinger, Frank, Hoffknecht, Petra, Tiemann, Markus, Heukamp, Lukas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353063/ https://www.ncbi.nlm.nih.gov/pubmed/32599951 http://dx.doi.org/10.3390/cancers12061685 |
Ejemplares similares
-
Comparison of Resistance Spectra after First and Second Line Osimertinib Treatment Detected by Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2021) -
The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations
por: Jóri, Balázs, et al.
Publicado: (2023) -
Acquired G2032R Resistance Mutation in ROS1 to Lorlatinib Therapy Detected with Liquid Biopsy
por: Jóri, Balázs, et al.
Publicado: (2022) -
TP53 co-mutations in EGFR mutated patients in NSCLC stage IV: A strong predictive factor of ORR, PFS and OS in EGFR mt+ NSCLC
por: Roeper, Julia, et al.
Publicado: (2020) -
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy
por: Falk, Markus, et al.
Publicado: (2023)